CEL — Celadon Pharmaceuticals Share Price
Last trade - 00:00- £4.47m
- £9.26m
- £0.08m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.84 | ||
| Price to Tang. Book | 2.08 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 34.42 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -65.81% | ||
| Return on Equity | -192.32% | ||
| Operating Margin | -3839.23% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | 0 | 0.02 | 0.07 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Celadon Pharmaceuticals Plc is a United Kingdom-based pharmaceutical company. The Company is engaged in research, cultivation, manufacturing, and supply of cannabinoid-based medicines. The Company is focused on growing indoor hydroponic cannabis initially for the chronic pain market. It is also focused on improving the quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based medicines for other conditions, such as autism. The Company's facility comprises an indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. It also has a minority interest in early-stage biopharma Kingdom therapeutics. The Company's subsidiary, LVL Health is a medical cannabis clinic for chronic pain that owns a medicines and healthcare products regulatory agency (MHRA) conditionally approved cannabis trial using cannabis-based medicinal products to treat chronic pain in the United Kingdom.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- August 31st, 2018
- Public Since
- October 19th, 2018
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 68,845,807
- Address
- 32-33 Cowcross Street, London, EC1M 6DF
- Web
- https://celadonpharma.com/
- Phone
- +44 2031500252
- Auditors
- RSM UK Audit LLP
Latest News for CEL
Upcoming Events for CEL
Full Year 2024 Celadon Pharmaceuticals PLC Earnings Release
Celadon Pharmaceuticals PLC Annual Shareholders Meeting
Half Year 2025 Celadon Pharmaceuticals PLC Earnings Release
Similar to CEL
Alliance Pharma
London Stock Exchange
Animalcare
London Stock Exchange
AstraZeneca
London Stock Exchange
Beximco Pharmaceuticals
London Stock Exchange
BSF Enterprise
London Stock Exchange
FAQ
As of Today at 01:50 UTC, shares in Celadon Pharmaceuticals are trading at 6.50p. This share price information is delayed by 15 minutes.
Shares in Celadon Pharmaceuticals last closed at 6.50p and the price had moved by -93.81% over the past 365 days. In terms of relative price strength the Celadon Pharmaceuticals share price has underperformed the FTSE All Share Index by -93.98% over the past year.
The overall consensus recommendation for Celadon Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCeladon Pharmaceuticals does not currently pay a dividend.
Celadon Pharmaceuticals does not currently pay a dividend.
Celadon Pharmaceuticals does not currently pay a dividend.
To buy shares in Celadon Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 6.50p, shares in Celadon Pharmaceuticals had a market capitalisation of £4.47m.
Here are the trading details for Celadon Pharmaceuticals:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: CEL
Based on an overall assessment of its quality, value and momentum Celadon Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Celadon Pharmaceuticals is 235.00p. That is 3515.38% above the last closing price of 6.50p.
Analysts covering Celadon Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Celadon Pharmaceuticals. Over the past six months, its share price has underperformed the FTSE All Share Index by -78.07%.
As of the last closing price of 6.50p, shares in Celadon Pharmaceuticals were trading -74.47% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Celadon Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 6.50p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Celadon Pharmaceuticals' directors